Related Experiment Video
Updated: Jul 22, 2025
10:52
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
Published on: December 10, 2021
2.6K
Huntington's Disease Clinical Trials Corner: August 2023
Carlos Estevez-Fraga1, Sarah J Tabrizi1, Edward J Wild1
1Huntington's Disease Centre, UCL Queen Square Institute of Neurology, London, UK.
Journal of Huntington'S Disease
|July 24, 2023
Summary
This update covers ongoing Huntington's disease clinical trials, including GENERATION HD2 (tominersen), AB-1001, and PROOF-HD findings. It provides a comprehensive list of current and registered trials for Huntington's disease research.
Area of Science:
- Neuroscience
- Genetics
- Clinical Research
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder.
- There is a critical need for effective therapeutic interventions for HD.
- Clinical trials are essential for advancing HD treatment strategies.
Purpose of the Study:
- To provide an update on key ongoing clinical trials for Huntington's disease.
- To discuss specific trials such as GENERATION HD2 (tominersen) and the Asklepios Biopharmaceutical/BrainVectis trial (AB-1001).
- To review recent findings from the PROOF-HD trial and compile a comprehensive list of all registered and ongoing HD clinical trials.
Main Methods:
- Review of ongoing clinical trial data and recent publications.
- Inclusion of information on registered trials from relevant databases.
- Expert commentary on trial progress and findings.
Main Results:
- The update details the status and scope of the GENERATION HD2 and AB-1001 trials.
- Recent findings from the PROOF-HD trial are discussed.
- A comprehensive list of currently registered and ongoing Huntington's disease clinical trials is presented.
Conclusions:
- The landscape of Huntington's disease clinical research is active and evolving.
- Continued monitoring of these trials is crucial for understanding therapeutic potential.
- This overview serves as a valuable resource for researchers, clinicians, and patients.
Related Concept Videos
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
01:16Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
01:24Parkinson's Disease: Treatment
301
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
301
01:22Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
01:15Parkinson's Disease: Overview
601
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
601
01:26Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525